Deals this week: Respicardia, Bigfoot Biomedical, Eyenovia

22 December 2017 (Last Updated November 22nd, 2018 11:31)

Respicardia Inc has secured $58.5m in a financing round led by Zoll Medical Corporation and existing investors.

Respicardia Inc has secured $58.5m in a financing round led by Zoll Medical Corporation and existing investors.

Based in the US, Respicardia is a medical technology company, while Zoll Medical, also based in the US, is a medical devices and related software solutions provider.

Respicardia plans to use the funds towards commercialisation and development of its central sleep apnea system remedē®.

Bigfoot Biomedical Inc has secured $37m in a series B financing round led by Quadrant Capital Advisors Inc and Janus Henderson Investors.

The company plans to use the funds towards the development of its class III medical device systems, including Bigfoot Loop and Bigfoot Inject.

US-based ophthalmic device company Eyenovia Inc plans to raise $35m through an initial public offering of shares of its common stock. It has filed a registration statement with the US Securities and Exchange Commission (SEC) for the same.

The company plans to use the funds to carry out phase III clinical trials on its MicroProst and MicroStat products.

Tandem Diabetes Care (TDC) Inc plans to raise $10.74m through a public offering of securities.

“The company plans to use the funds to carry out phase III clinical trials on its MicroProst and MicroStat products.”

The US-based company will offer a combination of securities, including common stock, preferred stock, warrants or units in one or more offerings.

The company plans to use the funds towards working capital and general corporate purposes.

Chinese investment company Great Belief International Ltd (GBIL) has announced the acquisition of minimally invasive surgical robot SurgiBot from US-based medical device company TransEnterix Inc.

The transaction includes the sale of all assets related to SurgiBot, including intellectual property for $15m.

The acquisition will enable GBIL to market SurgiBot in China.

Australian company Uscom Ltd has raised A$1.75m ($1.34m) through the private placement of 13 million new shares priced at A$0.135 ($0.103) a share.

The company plans to use the funds to complete outstanding orders and recruit clinical support and marketing staff.